Tag

Allergic Rhinoconjunctivitis archivos - Bilastina

rinitis alérgica y covid-19

Clinical presentation at the onset of COVID-19 and allergic rhinoconjunctivitis

By | Artículos seleccionados, Selected articles

Fabio Ferreli, Francesca Gaino, Elena Russo, Matteo Di Bari, Francesca Pirola, Andrea Costantino, Luca Malvezzi, Armando De Virgilio, Giovanni Colombo, Giovanni Paoletti, Emanuela Morenghi, Giorgio Walter Canonica, Giuseppe Spriano, Enrico Heffler, Giuseppe Mercante

J Allergy Clin Immunol Pract . 2020 Aug 18;S2213-2198(20)30823-0. doi: 10.1016/j.jaip.2020.08.009. Online ahead of print.

COVID-19 is characterized by various clinical conditions, from mild symptoms to pneumonia and death. Mild symptoms, such as nasal and ocular manifestations, can be confused with allergic rhinoconjunctivitis at the onset. This article describes the differences that let one distinguish COVID-19 and allergic rhinoconjunctivitis.

This study included 204 patients that were infected with coronavirus were included. They were retrospectively studied via telephone interview, where they were requested to complete a validated questionnaire, The Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ), which evaluated a series of 14 signs and symptoms on a scale from 0 to 6, indicating “not troubled” and “extremely troubled”, respectively. Patients were also asked to compare the manifestations of their last allergic symptomatic period with COVID-19 manifestations and to evaluate their sense of taste and/or smell.

Among all 204 participants, 22 were also affected by allergic rhinoconjunctivitis. Clinical manifestations of allergic rhinoconjunctivitis compared with those at the onset of COVID-19 were defined as “completely different” by 15 patients (68,2%), “different” by 3 (13.6%), and “similar” by 4 (18,2%). The two clinical presentations were never reported as “identical”.

Although COVID-19 may present some overlap in symptoms with seasonal allergies, the MiniRQLQ scored significantly different between allergic rhinoconjunctivitis and COVID-19. Also, in this study, there were no differences in taste and smell dysfunction reported. Patients with allergic rhinoconjunctivitis are familiar with its symptoms and were able to distinguish them from COVID-19 rhinoconjunctival manifestations.

This document is only available for registered healthcare professionals

Login
bilastina

Bilastine: a lifetime companion for the treatment of allergies

By | Articles about Bilastine

Martin K. Church, Marysia Tiongco-Rectob, Erminia Ridoloc and Zoltan Novàk.

Bilastine is a potent and highly selective H1-antihistamine approved for the treatment of allergic rhinoconjunctivitis and urticaria. This article summarizes available data on the use of bilastine in the treatment of allergic disorders in different age groups, including younger and older adults, and school-age children and adolescents.

This document is only available for registered healthcare professionals

Login
Reproducibility of nasal allergen challenge responses in adults with allergic rhinitis

Reproducibility of nasal allergen challenge responses in adults with allergic rhinitis

By | Selected articles

Pantin CT, Southworth T, Wetzel K, Singh D.

Allergic rhinitis is characterized by nasal inflammation that occurs in response to allergen exposure. Reproducibility of nasal secretion cytokine responses and physiological measurements are needed to determine the optimum measurements and power calculations for future studies. A group of investigators have investigated the reproducibility of nasal cytokine measurements, using ready-to-use polyvinyl acetate sponges to collect nasal secretions, and measurements of nasal physiological responses.

This study included twelve participants with allergic rhinitis and no history of respiratory disease, and twelve with asthma and allergic rhinitis. They were submitted to a nasal allergen challenge which was repeated 7-14 days later. Participants had an increase in IL-5, and in cytokines CCL11 and CXCL8 responses post-challenge (all P<0.05). Acoustic rhinometry provided good to excellent reproducibility and rhinomanometry had lower reproducibility with greater variation, with some participants unable to perform the measurement. Multiplex immunoassays provided greater sensitivity for cytokine CCL11 measurements. There were no differences between allergic rhinitis patients with and without asthma.

They concluded that polyvinyl acetate sponges are a practical and reproducible way to sample nasal secretions and acoustic rhinometry is a practical and reproducible method for assessing physiological responses

This document is only available for registered healthcare professionals.

login
ácaros del polvo

Determination of the minimally important difference in a nasal symptom score in house dust mite allergy

By | Selected articles

Devillier P, Brüning H, Bergmann KC.

House dust mite (HDM) allergens are responsible for the most prevalent persistent respiratory allergies. Clinical trials in this field often use a four-component nasal symptom score (T4NSS) as a measure of efficacy.

The MID for improvement in the T4NSS is at least -0.90 units in children, adolescents and adults suffering from HDM-induced AR. This value could be rounded up to -1 unit for convenience.

This document is only available for registered healthcare professionals

Login
Rinoconjuntivitis alérgica

Early molecular biomarkers predicting the evolution of allergic rhinitis and its comorbidities: A longitudinal multicenter study of a patient cohort.

By | Selected articles
Cipriani F, Tripodi S, Panetta V, Perna S, Potapova E, Dondi A, Bernardini R, Caffarelli C, Casani A, Cervone R, Chini L, Comberiati P, De Castro G, Miraglia Del Giudice M, Dello Iacono I, Di Rienzo Businco A, Gallucci M, Giannetti A, Mastrorilli C, Moschese V, Pelosi S, Sfika I, Varin E, Villella V, Zicari AM, Brindisi G, Ricci G, Matricardi PM; Italian Pediatric Allergy Network (I-PAN).

In this study are investigated predictive biomarkers of disease evolution in a large cohort of children with seasonal allergic rhinoconjunctivitis (SAR).

This document is only available for registered healthcare professionals

Login
Estudio bilastina en niños de 2 a 12 años

Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases

By | Articles about Bilastine
Novák Z, Yáñez A, Kiss I, Kuna P, Tortajada-Girbés M, Valiente R; “Bilastine Paediatric Safety Study Group”.

Bilastine 10 mg had a safety and tolerability profile similar to that of placebo in children aged 2 to <12 years with allergic rhinoconjunctivitis or chronic urticaria.

This document is only available for registered healthcare professionals

Login

La información que está a punto de visualizar está dirigida únicamente a los profesionales sanitarios aptos para prescribir o dispensar medicamentos. La correcta utilización de su contenido requiere de formación como profesional sanitario.

Debe hacer clic en Aceptar para confirmar que es usted profesional de la salud y continuar con la navegación.

ACEPTAR